KIGEN
10.8.2021 15:02:15 CEST | Business Wire | Press release
AT&T and Kigen are working together to help customers streamline their supply chains and reduce the time to market for enterprises who want to leverage SIM, embedded SIM (eSIM) and integrated SIM (iSIM) secured connectivity deep in their IoT devices.
Kigen’s SIM OS, data generation and key management services will allow AT&T to offer a broader selection for integrated SIM solutions. Manufacturers will enjoy greater flexibility by sourcing their AT&T SIM at the stage of the device manufacturing process that best suits the customer. This might be at the point of contract manufacturing, module supply, or even at the chipset level by leveraging an integrated SIM and merging both chip and SIM into a single component.
Reducing complexity and accelerating time to market will attract new customers that are embarking on their cellular IoT transformation, or those that are accelerating the adoption of secure connected goods and bringing them to market sooner as a result of streamlining the chipset and SIM evaluation process.
Prior to this, device manufacturers had to purchase multiple SIM SKUs for each end-customer or market, which has complicated global product rollouts. Access to a new cache of SIMs that are compatible with cellular chipsets and secure IC vendors offers additional flexibility that results in supply chain optimisation. This streamlined approach also simplifies the manufacturing process by allowing suppliers, OEMs and licensees to identify the ideal SIM solution earlier in the design process, meaning device estates can scale sooner upon deployment.
Kigen’s SIM OS, data generation, and key management services will enable seamless access to AT&T’s Network across LTE, LTE-M, and NB-IoT technologies. Simple integration makes it easier for new entrants and established players alike to adopt cellular IoT in their devices sooner while futureproofing them with 5G readiness.
“By working with Kigen we can help enable device manufacturers to streamline their IoT device development and manufacturing.” Said William Stovall, vice president, Mobility, IoT and 5G, AT&T. “This collaboration will also offer AT&T customers the ability to bring more innovative and secure features to market sooner.”
“Scale is both cellular IoT’s most significant opportunity and hurdle. Removing the complications of placing security at the heart of IoT devices so that businesses can focus on accelerating their products is key,” said Vincent Korstanje, CEO, Kigen. “The combination of Kigen’s solutions across all types of SIM from our ecosystem with AT&T’s connectivity simplifies how businesses choose the right type of security, tuned to their manufacturing needs; offering trusted IoT that scales.”
About Kigen
At Kigen, we are making the future of securing connectivity simple. As simple as can be. As a wholly owned subsidiary of Arm, together with our partners and customers, we are unlocking new opportunities as (integrated) eSIM becomes the cornerstone of connected devices security. Our industry-leading SIM OS products enable over 2 billion SIMs. Our remote SIM provisioning and eSIM services drive this momentum further placing us amongst top 5 SIM vendors globally. Our 135 employees globally are guided by the vision of a world where every device can connect securely and reliably. For more information, go to kigen.com or speak to us on @Kigen_Ltd on Twitter and LinkedIn about #futureofSIM.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom